Birdwatch Note
2023-08-20 07:52:35 UTC - NOT_MISLEADING
NNN. Personal opinion. To date, at least 3 pharmacovigilance analyses suggest potential kidney damage associated with remdesivir use. https://pubmed.ncbi.nlm.nih.gov/33340409/ https://pubmed.ncbi.nlm.nih.gov/34787281/ https://pubmed.ncbi.nlm.nih.gov/35401177/ According to the FDA, one of the most common adverse reactions is increased ALT, associated with liver injury or disease. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214787s019lbl.pdf
Written by 66BF7B95140FB05BD1B0FFEE3495482BFB1BFE0368035B94A62C0DC49D493222
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1692921944578879505
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1693169141476450544
- noteId - 1693169141476450544
- participantId -
- noteAuthorParticipantId - 66BF7B95140FB05BD1B0FFEE3495482BFB1BFE0368035B94A62C0DC49D493222 Participant Details
- createdAtMillis - 1692517955546
- tweetId - 1692921944578879505
- classification - NOT_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 0
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 0
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 1
- trustworthySources - 1
- summary
- NNN. Personal opinion. To date, at least 3 pharmacovigilance analyses suggest potential kidney damage associated with remdesivir use. https://pubmed.ncbi.nlm.nih.gov/33340409/ https://pubmed.ncbi.nlm.nih.gov/34787281/ https://pubmed.ncbi.nlm.nih.gov/35401177/ According to the FDA, one of the most common adverse reactions is increased ALT, associated with liver injury or disease. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214787s019lbl.pdf
Note Status History
| createdAt | timestampMillisOfFirstNonNMRStatus | firstNonNMRStatus | timestampMillisOfCurrentStatus | currentStatus | timestampMillisOfLatestNonNMRStatus | mostRecentNonNMRStatus | participantId |
| 2023-08-20 07:52:35 UTC (1692517955546) |
1969-12-31 23:59:59 UTC (-1) |
2023-08-21 03:10:36 UTC (1692587436428) |
NEEDS_MORE_RATINGS | 1969-12-31 23:59:59 UTC (-1) |
Note Ratings
| rated at | rated by | |
| 2023-08-20 18:24:34 -0500 | Rating Details | |
| 2023-08-20 18:13:06 -0500 | Rating Details | |
| 2023-08-20 17:30:57 -0500 | Rating Details | |
| 2023-08-20 16:19:13 -0500 | Rating Details | |
| 2023-08-20 14:17:44 -0500 | Rating Details | |
| 2023-08-20 13:08:22 -0500 | Rating Details | |
| 2023-08-20 13:05:14 -0500 | Rating Details | |
| 2023-08-20 11:39:11 -0500 | Rating Details | |
| 2023-08-20 11:22:36 -0500 | Rating Details | |
| 2023-08-20 11:04:55 -0500 | Rating Details | |
| 2023-08-20 10:53:58 -0500 | Rating Details | |
| 2023-08-20 09:37:54 -0500 | Rating Details | |
| 2023-08-20 09:15:55 -0500 | Rating Details | |
| 2023-08-20 09:13:24 -0500 | Rating Details | |
| 2023-08-20 09:10:34 -0500 | Rating Details | |
| 2023-08-20 09:09:35 -0500 | Rating Details | |
| 2023-08-20 08:59:12 -0500 | Rating Details | |
| 2023-08-20 08:57:11 -0500 | Rating Details | |
| 2023-08-20 08:51:49 -0500 | Rating Details | |
| 2023-08-20 08:47:25 -0500 | Rating Details | |
| 2023-08-20 08:33:33 -0500 | Rating Details | |
| 2023-08-20 08:28:28 -0500 | Rating Details | |
| 2023-08-20 07:18:25 -0500 | Rating Details | |
| 2023-08-20 06:57:48 -0500 | Rating Details | |
| 2023-08-20 06:52:05 -0500 | Rating Details | |
| 2023-08-20 05:39:39 -0500 | Rating Details | |
| 2023-08-20 05:12:52 -0500 | Rating Details | |
| 2023-08-20 05:02:55 -0500 | Rating Details | |
| 2023-08-20 05:01:54 -0500 | Rating Details | |
| 2023-08-20 04:10:02 -0500 | Rating Details | |
| 2023-08-20 03:52:16 -0500 | Rating Details | |
| 2023-08-20 03:42:28 -0500 | Rating Details | |
| 2023-08-20 03:07:26 -0500 | Rating Details | |
| 2023-08-20 03:04:26 -0500 | Rating Details | |
| 2023-08-21 13:01:48 -0500 | Rating Details | |
| 2023-08-21 08:29:05 -0500 | Rating Details | |
| 2023-08-21 08:05:57 -0500 | Rating Details | |
| 2023-08-20 23:40:35 -0500 | Rating Details | |
| 2023-08-20 22:36:26 -0500 | Rating Details | |
| 2023-08-20 20:26:47 -0500 | Rating Details | |
| 2023-08-20 20:13:46 -0500 | Rating Details | |
| 2023-08-22 12:28:09 -0500 | Rating Details | |
| 2023-08-20 20:52:14 -0500 | Rating Details | |
| 2023-08-20 19:11:25 -0500 | Rating Details | |
| 2023-08-20 18:49:57 -0500 | Rating Details | |
| 2023-08-20 12:39:22 -0500 | Rating Details | |
| 2023-08-20 09:47:55 -0500 | Rating Details | |
| 2023-08-20 09:36:56 -0500 | Rating Details | |
| 2023-08-20 08:46:55 -0500 | Rating Details | |
| 2023-08-20 08:44:26 -0500 | Rating Details | |
| 2023-08-26 12:04:49 -0500 | Rating Details | |
| 2023-08-27 21:01:20 -0500 | Rating Details | |
| 2023-08-29 07:45:30 -0500 | Rating Details | |
| 2024-03-09 02:02:58 -0600 | Rating Details |